Minor tweaks may be all the adjustments needed to the Risk Evaluation and Mitigation Strategy for Alexion Pharmaceuticals Inc.’s Soliris (eculizumab), according to briefing documents released ahead of the FDA Drug Safety and Risk Management Advisory Committee’s Nov. 18 meeting.
FDA and Alexion said the current REMS with elements to assure safe use (ETASU) appears to be meeting its goals of reducing the occurrence and morbidity of meningococcal infections and informing health care providers and patients about this serious risk
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?